duce
human
macrophag
model
system
activ
pbmc
well
establish
clinic
immunolog
sever
decad
allow
standard
tcell
activ
tcellmacrophag
interact
certainli
inform
myelomonocyt
tumor
cell
line
relev
vivo
test
approach
alreadi
use
test
antiinflammatori
drug
year
reproduc
result
even
assay
blood
differ
donor
dosedepend
effect
detect
compound
resveratrol
drug
atorvastatin
beverag
welldescrib
antiatherogen
potenti
green
black
tea
beer
model
system
would
measur
product
stimul
macrophag
readout
clearli
relev
atherosclerosi
inflamm
pivot
howev
pbmc
model
draw
attent
role
tcellmacrophag
interplay
highli
relev
pathogenesi
atherosclerosi
acknowledg
exist
data
role
proinflammatori
cytokin
process
atherogenesi
inflammatori
condit
induc
deplet
antioxid
system
caus
oxid
stress
probabl
import
trigger
product
reactiv
oxygen
speci
macrophag
consid
utmost
relev
atherogenesi
vitro
pbmc
system
fulli
accord
notion
macrophag
product
measur
valid
vitro
vivo
neopterin
product
tryptophan
degrad
induc
macrophag
thu
reflect
macrophag
activ
coronari
heart
diseas
increas
neopterin
concentr
correl
tryptophan
degrad
activ
diseas
also
predict
coronari
event
sensit
method
wide
use
creactiv
protein
measur
contrast
studi
involv
cytokin
atherogenesi
stem
almost
exclus
vitro
experi
summari
combin
studi
effect
cell
macrophag
healthi
donor
appear
superior
use
myelomonocyt
cell
line
altern
approach
pbmc
prepar
provid
insight
signal
cascad
especi
initi
cell
monitor
biochem
effect
neopterin
format
tryptophan
degrad
reveal
stabl
result
quantit
term
monitor
cytokin
product
moreov
strategi
monitor
net
effect
variou
proand
antiinflammatori
cascad
initi
stimul
immun
respons
vitro
vivo
provid
data
influenc
test
compound
whole
cascad
event
final
readout
system
seem
particularli
suit
test
antiinflammatori
effect
compound
enhanc
product
neopterin
acceler
degrad
tryptophan
close
relat
pathogenesi
variou
diseas
inflammatori
process
involv
editor
present
studi
aim
investig
whether
serum
concentr
serum
amyloid
saa
measur
surfaceenhanc
laser
desorptionion
seldi
proteinchip
technolog
elisa
use
differenti
patient
sever
acut
respiratori
syndrom
sar
nonsar
patient
suspect
case
sar
outbreak
period
recent
report
kang
et
al
mean
intens
protein
peak
mz
identifi
seldi
proteinchip
technolog
sar
patient
group
time
greater
intens
correspond
peak
control
patient
group
seldi
peak
observ
previous
anoth
proteom
studi
similar
experiment
condit
identifi
saa
recent
studi
yip
et
al
intens
seldi
peak
mz
identifi
saa
significantli
higher
sar
patient
group
control
group
similar
increas
peak
also
found
pediatr
patient
sar
studi
suggest
saa
use
diagnosi
sar
studi
control
case
either
healthi
person
patient
viral
infect
clinic
unfortun
degre
similar
symptom
sar
control
group
particip
time
point
blood
collect
consid
studi
perspect
infecti
diseas
diagnosi
tri
differenti
healthi
person
infect
patient
rather
tri
identifi
diseas
caus
symptom
patient
present
similar
symptom
bear
mind
issu
recent
attempt
profil
compar
serum
proteom
adult
patient
earli
stage
sar
infect
adult
nonsar
patient
suspect
case
sar
outbreak
period
found
specif
seldi
peak
sera
adult
sar
patient
howev
peak
correspond
saa
identifi
sarsspecif
featur
led
us
question
whether
saa
use
biomark
diagnosi
sar
studi
nonsar
patient
symptom
similar
sar
patient
admiss
admit
hospit
sar
patient
later
shown
neg
sar
coronaviru
cov
infect
antisarscov
antibodi
serolog
test
least
week
onset
symptom
saa
concentr
serum
sampl
nonsar
case
sar
case
remain
seldi
studi
determin
antisaa
elisa
accord
manufactur
instruct
biosourc
intern
use
proteinchip
array
also
call
ph
bind
buffer
tolson
et
al
show
peak
mz
mz
mz
fulllength
saa
desarginin
desargininedesserin
variant
nh
terminu
respect
seldi
dataset
obtain
proteinchip
type
bind
condit
seldi
peak
similar
mz
valu
mean
valu
mz
mz
mz
spearman
rank
correl
analysi
show
normal
intens
peak
correl
highli
serum
concentr
valu
obtain
elisa
correl
coeffici
p
valu
tabl
high
correl
strongli
suggest
seldi
peak
mz
mz
mz
fulllength
saa
desarginin
desargininedesserin
variant
nh
terminu
contrast
previou
seldi
studi
normal
intens
peak
significantli
lower
adult
sar
patient
instead
higher
tabl
analyz
elisa
data
found
serum
saa
concentr
greatli
increas
sar
nonsar
patient
group
mean
serum
saa
concentr
sar
nonsar
patient
group
higher
upper
limit
refer
interv
mgl
respect
consist
seldi
data
serum
saa
concentr
significantli
lower
sar
patient
group
p
tabl
result
seldi
proteinchip
assay
elisa
indic
serum
saa
use
differenti
sar
patient
nonsar
patient
suspect
case
sar
outbreak
period
serum
saa
increas
sar
patient
howev
could
exclud
possibl
could
use
combin
serum
marker
develop
classif
model
sar
diagnosi
serum
saa
acutephas
reactant
shown
increas
variou
type
viral
bacteri
infect
regardless
type
infect
serum
saa
concentr
increas
mgl
degre
increas
may
reflect
sever
ill
indic
caus
sar
patient
group
found
saa
peak
serum
concentr
correl
significantli
serum
creactiv
protein
concentr
tabl
infecti
diseas
suggest
increas
serum
saa
caus
mainli
inflammatori
respons
sar
infect
conclus
data
seldi
proteinchip
profil
studi
elisa
studi
support
content
increas
serum
saa
indic
sar
contrast
result
strongli
suggest
serum
saa
concentr
use
differenti
sar
patient
nonsar
patient
suspect
case
sar
outbreak
period
